General description
二肽基肽酶IV(DPP IV)属于脯氨酰特异性蛋白酶家族成员。它是一种二聚体II型整合膜糖蛋白，广泛表达于上皮和非上皮组织中。主要表达于肾脏和结肠。
Application
二肽基肽酶IV抑制剂已用于体内急性研究，评估小鼠中血浆胰高血糖素样肽(GLP-1)对特定分泌剂的快速反应。
Biochem/physiol Actions
二肽基肽酶IV(DPP IV)是胰高血糖素样肽(GLP-1)、胰岛素刺激激素和葡萄糖依赖性胰岛素释放肽(GIP)的调节剂。它是治疗2型糖尿病(T2DM)的重要靶点。DPP-4抑制剂可延长GLP-1和GIP活性，对于维持血糖稳态十分重要。与早前口服降糖药物相比，这类抑制剂对血糖控制的增强作用持续时间更久。DPP-4也可作为结合蛋白，及胞外因子配体。
Other Notes
Ile-Pro-Ile
Still not finding the right product?
Explore all of our products under 二肽基肽酶 IV 抑制剂 I
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Francisco Alejandro Lagunas-Rangel et al.
Biomedicines, 11(11) (2023-11-25)
Dipeptidyl peptidase 4 (DPP4) inhibitors, commonly known as gliptins, have been an integral part of the treatment of type 2 diabetes mellitus (T2DM) for several years. Despite their remarkable efficacy in lowering glucose levels and their compatibility with other hypoglycemic
Rajesh Gupta et al.
Current drug targets, 10(1), 71-87 (2009-01-20)
Dipeptidyl peptidase IV (DPP IV) is a key regulator of insulin-stimulating hormones, glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thus it is a promising target for the treatment of Type 2 Diabetes mellitus (T2DM). Inhibition of plasma DPP IV
Sebastiano Bruno Solerte et al.
Acta diabetologica, 57(7), 779-783 (2020-06-09)
SARS-CoV-2 causes severe respiratory syndrome (COVID-19) with high mortality due to a direct cytotoxic viral effect and a severe systemic inflammation. We are herein discussing a possible novel therapeutic tool for COVID-19. Virus binds to the cell surface receptor ACE2;
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| D3822-5MG | 04061833218303 |